Ph I CAR-T cell therapy trial to use Horizon Discovery tech

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/bluebay2014)
(Image: Getty/bluebay2014)

Related tags Horizon Discovery phase I Clinical trial IND applications Technology CAR-T

The Phase I clinical trial is slated for early 2020 and will be first CAR-T cell therapy clinical trial to use Horizon Discovery’s technology, according to the company.

Celyad, a clinical-stage biopharmaceutical company, has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) for its autologous NKG2D-based CAR-T cell therapy, CYAD-02, which uses Horizon Discovery’s​ SMARTvector shRNA technology.

The technology uses a SMARTvector short hairpin RNA (shRNA) algorithm to design target shRNA sequences with high specificity to ensure optimal gene silencing, according to the company.

The Phase I dose-escalation trial will involve a preconditioning chemotherapy (CyFlu) in patients with relapse/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It is expected to begin in early 2020.

Horizon Discovery CEO Terry Pizzie, said in a statement: “We see great potential for shRNA technology in the optimization of next-generation cell therapies. The success of this IND filing is testament to the strength of our relationship with Celyad, and the powerful combination of Horizon’s SMARTvector shRNA platform with Celyad’s CAR-T expertise.”

As per the companies’ agreement, Horizon will receive an undisclosed milestone payment for the successful IND filing.

Related topics Clinical Development Phase I-II

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars